Akari Therapeutics

Home » Akari Therapeutics

Secondary

Akari Therapeutics

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression.

Symbol

AKTX

Last Closing Price
$6.40

Shares
3,000,000

Effective Date
October 18, 2017

Underwriters
Cantor Fitzgerald, Willaim Blair, Canaccord Genuity

To view the prospectus for Akari Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253